(Q38271032)

1 September 2017

1 reference

title

Current treatment landscape for relapsed and/or refractory multiple myeloma (English)

1 reference

1 September 2017

author

Athanasios Dimopoulos

object named as

Meletios A Dimopoulos

series ordinal

1

0 references

Philippe Moreau

series ordinal

3

object named as

Philippe Moreau

1 reference

1 September 2017

2

Paul G Richardson

1 reference

1 September 2017

4

Kenneth C Anderson

1 reference

1 September 2017

language of work or name

English

0 references

publication date

25 November 2014

1 reference

Nature Reviews Clinical Oncology

1 September 2017

published in

1 reference

1 September 2017

volume

12

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

42-54

1 reference

Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Thalidomide for treatment of multiple myeloma: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Thalidomide and dexamethasone combination for refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Apoptosis in multiple myeloma: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

European perspective on multiple myeloma treatment strategies: update following recent congresses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Current and emerging treatment options for patients with relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Management of double-refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Current approaches for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Current multiple myeloma treatment strategies with novel agents: a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Proteasome inhibitors in multiple myeloma: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Targeted resequencing of 52 bone marrow failure genes in patients with aplastic anemia reveals an increased frequency of novel variants of unknown significance only in SLX4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

The emerging role of novel therapies for the treatment of relapsed myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Lenalidomide and venous thrombosis in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.200

Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib

31 March 2020

1 reference

12 December 2020

Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma

1 reference

12 December 2020

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

1 reference

12 December 2020

How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.

1 reference

12 December 2020

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

1 reference

12 December 2020

10.1038/NRCLINONC.2014.200

Identifiers

DOI

1 reference

1 September 2017

1 reference